医学
内科学
肾脏疾病
随机对照试验
狼牙棒
糖尿病
荟萃分析
安慰剂
2型糖尿病
2型糖尿病
不利影响
内分泌学
病理
心肌梗塞
经皮冠状动脉介入治疗
替代医学
作者
Haiyan Cao,Youxia Liu,Zhixia Tian,Yuhang Lian,Junya Jia,Ming Liu,Li Dong
标识
DOI:10.1016/j.diabres.2021.109033
摘要
Background A systematic review and meta-analysis was performed to assess the kidney and cardiovascular (CV) outcomes of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3b-4. Method We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials (RCTs). Medline, Embase, and the Cochrane Central were searched for available trials up to Jan 18, 2021. Results From identifying 1892 citations, we included nine studies into quantitative analyses with a total of 6521 participants. In the patients with T2DM and CKD stage 3b-4, SGLT2 inhibitors significantly decreased the risk of the primary kidney outcome (HR 0.65, 95% CI 0.55–0.76) and slowed the decline in eGFR slope with a difference between treatment and control of 0.46 ml/min/1.73 m2 per year (95% CI 0.37–0.55). SGLT2 inhibitors also reduced the risk of the major adverse cardiovascular events (MACE) (HR 0.75, 95% CI 0.60–0.93). Conclusions SGLT2 inhibitors can reduce the risk of kidney disease and MACE outcomes for patients with T2DM and CKD stage 3b-4, which may be the most beneficial effects observed in the included trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI